Thomas Videbaek
Chief Executive Officer presso Novozymes BioloAg A/S
Profilo
Il Dr. Thomas Videbaek è presidente di Protera SAS, amministratore non esecutivo indipendente di Camlin Fine Sciences Ltd. e amministratore delegato di Novozymes BioloAg A/S. Fa parte del consiglio di amministrazione di Camlin Fine Sciences Ltd., Novozymes Biopharma DK A/S, Evolva SA e Albumedix A/S. Il Dr. Videbaek è stato precedentemente impiegato come direttore non esecutivo di Evolva Holding SA, come Executive VP-People, Sustainability & Brand di Novozymes A/S, come Vice Presidente-Cereal Food & Beverage Marketing di Novozymes Switzerland AG e come Direttore-Strategic Marketing di Novo Nordisk A/S. È stato anche membro del consiglio di amministrazione di Novozymes BioAg Group e Beta Renewables SpA. Si è laureato alla Copenhagen Business School, si è laureato alla Technical University of Denmark e ha conseguito il dottorato alla Technical University of Denmark.
Posizioni attive di Thomas Videbaek
Società | Posizione | Inizio |
---|---|---|
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Director/Board Member | - |
Novozymes Biopharma DK A/S
Novozymes Biopharma DK A/S Pharmaceuticals: MajorHealth Technology Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark. | Director/Board Member | - |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Director/Board Member | - |
Novozymes BioloAg A/S
Novozymes BioloAg A/S BiotechnologyHealth Technology Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark. | Chief Executive Officer | 22/10/2007 |
Protera SAS
Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Chairman | 06/04/2021 |
Evolva AG | Director/Board Member | - |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Director/Board Member | - |
Precedenti posizioni note di Thomas Videbaek
Società | Posizione | Fine |
---|---|---|
CAMLIN FINE SCIENCES LIMITED | Director/Board Member | 23/02/2023 |
EVOLVA HOLDING SA | Director/Board Member | 15/04/2020 |
░░░░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di Thomas Videbaek
Copenhagen Business School | Undergraduate Degree |
Technical University of Denmark | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
CAMLIN FINE SCIENCES LIMITED | Process Industries |
EVOLVA HOLDING SA | Consumer Non-Durables |
Aziende private | 11 |
---|---|
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Novozymes BioAg Group
Novozymes BioAg Group BiotechnologyHealth Technology Novozymes BioAg Group was developed and manufactured microbial products. The company was founded in 1980 and was headquartered in Saskatoon, Canada. | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Novozymes BioloAg A/S
Novozymes BioloAg A/S BiotechnologyHealth Technology Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark. | Health Technology |
Novozymes Biopharma DK A/S
Novozymes Biopharma DK A/S Pharmaceuticals: MajorHealth Technology Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark. | Health Technology |
Novozymes Switzerland AG | |
Beta Renewables SpA
Beta Renewables SpA Chemicals: Major DiversifiedProcess Industries Beta Renewables SpA develops bio fuels and biochemical compounds. The company was founded in 2011 and is headquartered in Tortona, Italy. | Process Industries |
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Health Technology |
Evolva AG | |
Protera SAS
Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Consumer Non-Durables |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Commercial Services |